Form 4: Veracyte Director Sells Shares Under 10b5-1 Plan
Insider Transaction Disclosure
Veracyte Director Karin Eastham sold 9,674 shares of common stock for a weighted average price of $40.0239 per share, executed under a pre-arranged 10b5-1 plan.
Summary
- Karin Eastham, a Director at Veracyte, Inc. (VCYT), disposed of 9,674 shares of common stock.
- The transaction occurred on November 5, 2025, at a weighted average sale price of $40.0239 per share.
- Individual sale prices for the transactions ranged from $40.00 to $40.70.
- The sale was executed pursuant to a Rule 10b5-1 plan, which was adopted by Karin Eastham on August 20, 2024.
- Following this transaction, Karin Eastham directly beneficially owns 13,554 shares of Veracyte common stock.
Sentiment
Score: 5
Explanation: The transaction is a pre-planned sale under a Rule 10b5-1 plan, which is generally considered a neutral event as it typically reflects personal financial planning rather than a reaction to new material non-public information about the company's performance or prospects.
Negatives
- A director's sale of shares, even under a 10b5-1 plan, reduces their direct ownership stake in the company.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This filing details an individual insider transaction and does not provide information directly related to broader industry trends or competitive landscape.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan Disclosure | The transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2024, indicating a pre-arranged trading strategy designed to comply with insider trading laws. | 08/20/2024 | Enhances transparency regarding insider transactions and demonstrates adherence to SEC regulations for planned stock sales. |
Stakeholder Impact
- Shareholders: The sale by a director slightly reduces insider ownership, which could be viewed neutrally given the 10b5-1 plan, or as a minor reduction in alignment of interests.
Key Dates
| Date | Description |
|---|---|
| 08/20/2024 | Date Rule 10b5-1 plan was adopted by the reporting person. |
| 11/05/2025 | Date of the reported transaction (sale of common stock). |
| 11/07/2025 | Date the Form 4 was signed. |
Keywords
VCYT, Veracyte, insider trading, Form 4, stock sale, 10b5-1 plan, director transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.